How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution!

Research output: Contribution to journalArticle

Original languageEnglish (US)
Pages (from-to)779-781
Number of pages3
JournalJournal of the National Cancer Institute
Volume88
Issue number12
DOIs
StatePublished - 1996

Fingerprint

Predictive Value of Tests
Suramin
Prostate-Specific Antigen
Survival Analysis
Tumor Biomarkers
Antineoplastic Agents
Prostatic Neoplasms
Clinical Trials

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{b997ebad2edc4fd19c5b14db55e037cb,
title = "How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution!",
author = "Mario Eisenberger and Nelson, {William G}",
year = "1996",
doi = "10.1093/jnci/88.12.779",
language = "English (US)",
volume = "88",
pages = "779--781",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution!

AU - Eisenberger, Mario

AU - Nelson, William G

PY - 1996

Y1 - 1996

UR - http://www.scopus.com/inward/record.url?scp=0029950084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029950084&partnerID=8YFLogxK

U2 - 10.1093/jnci/88.12.779

DO - 10.1093/jnci/88.12.779

M3 - Article

C2 - 8637038

AN - SCOPUS:0029950084

VL - 88

SP - 779

EP - 781

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 12

ER -